Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serenity: LY3074828 in active Crohn's disease
NL-OMON49704Phase 2Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of mirikizumab in Crohn's disease (4 arms), sponsored by Eli Lilly and Company. Started Jul 2017; status: recruiting.
02
Drugs
mirikizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON49704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49704.